Merck shuffles the Kelun deck again
Claudin18.2 is out, but the US big pharma opts in to a new project.
Pfizer takes on Merck in a new checkpoint
Pfizer’s LILRB1 x LILRB2 bispecific is about to enter the clinic.
Claudin18.2 expression clouds Elevation's big reveal
Western data on EO-3021 fail to live up to the billing of a Chinese trial.
Is this the end for MacroGenics’ vobra-duo?
The company stops dosing in the troubled Tamarack trial, and is going quiet until ESMO.
An unfamiliar name goes after familiar targets
Soon after filing to float in Hong Kong, Baili takes HER2 and DLL3-targeting ADCs into the clinic.
ESMO 2024 preview – conjugates in the spotlight
Early attention falls on ADCs originated by ProfoundBio, SystImmune, MediLink and Seagen.
